RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-5203
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_1423100; Gene model (P.falciparum): PF3D7_0814400; Gene product: putative phospholipase, DDHD1 (PA-PLA1, Pla1)
Phenotype Liver stage;
Last modified: 26 May 2022, 16:12
  *RMgm-5203
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption
Reference (PubMed-PMID number) Reference 1 (PMID number) : 35427579
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone Not applicable
Other information parent line
The mutant parasite was generated by
Name PI/ResearcherSrivastava PN, Mishra S
Name Group/DepartmentDivision of Molecular Microbiology and Immunology
Name InstituteCSIR-Central Drug Research Institute
CityLucknow
CountryIndia
Name of the mutant parasite
RMgm numberRMgm-5203
Principal namePla1-
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot different from wild type
Fertilization and ookineteNot different from wild type
OocystNot different from wild type
SporozoiteNot different from wild type
Liver stageSalivary gland sporozoite in vivo infectivity was checked by i.v injecting in C57BL/6 mice. Initially, 5,000 sporozoites from WT GFP or Pla1- were used, and while the appearance of blood-stage infection was observed on the third day in all mice infected with WT GFP, a delay of 2.5 – 3.5 days was observed in the appearance of Pla1- blood-stage infection.
To quantify the sporozoite invasion and subsequent development in the liver, we infected mice with 5x103 sporozoites and the liver parasite burden was quantified at 40 h p.i. by measuring the parasite 18S rRNA copy number using real-time PCR. There was no significant difference in liver parasite burdens between WT GFP and Pla1-. EEFs were also counted at 40 h p.i. in multiple experiments and no difference from wild type was observed, signifying normal productive invasion and development by Pla1- sporozoites (Fig. 4C). EEF growth was also monitored by measuring their areas at 40 h and 65 h p.i., with no significant difference from WT GFP. Subsequently, maturation of EEFs and the formation of merozoites was observed by anti-MSP1 staining. Both nuclear division and merozoite formation appeared normal in Pla1-EEFs. In vitro cell detachment was quantified for Pla1- and comparatively fewer detached cells (DCs) were detected floating in the cell culture medium even up to 70 h p.i. Evidence is presented that Pla1 has a role in merosome release.
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of Pla1

Protein (function)
A total of 22 genes have been identified thus far, having similarities to the representative members of at least one of the four groups of known phospholipases; PLA, PLB, PLC and PLD. Out of these, 15 have the α/β hydrolase fold, four have the patatin-like phospholipase (PLP) domain and the remaining three have lecithin:cholesterol acyltransferase (LCAT), exonuclease-endonuclease-phosphatase (EEP) and DDHD domains. An interesting class of enzymes is the intracellular PLA1 family. In most eukaryotes, there is only one enzyme of this family while there are three members in mammals. Early  characterization efforts identified a phosphatidic acid (PA) preferring phospholipase A1 (PAPLA1) a putative phospholipase, DDHD1 (PbPla1, PlasmoDB accession number: PBANKA_1423100), which is the only P. berghei homolog of PA-PLA1 (Pla1)

Phenotype
Salivary gland sporozoite in vivo infectivity was checked by i.v injecting in C57BL/6 mice. Initially, 5,000 sporozoites from WT GFP or Pla1- were used, and while the appearance of blood-stage infection was observed on the third day in all mice infected with WT GFP, a delay of 2.5 – 3.5 days was observed in the appearance of Pla1- blood-stage infection. To quantify the sporozoite invasion and subsequent development in the liver, we infected mice with 5x103 sporozoites and the liver parasite burden was quantified at  40  h p.i. by measuring the parasite 18S rRNA copy number using real-time PCR. There was no significant difference in liver parasite burdens between WT GFP and Pla1-. EEFs were also counted at 40 h p.i. in multiple experiments and no difference from wild type was observed, signifying normal productive invasion and development by Pla1- sporozoites (Fig. 4C). EEF growth was also monitored by measuring their areas at 40 h and 65 h p.i., with no significant difference from WT GFP. Subsequently, maturation of EEFs and the formation of merozoites was observed by anti-MSP1 staining. Both nuclear division and merozoite formation appeared normal in Pla1-EEFs. In vitro cell detachment was quantified for Pla1- and comparatively fewer detached cells  (DCs) were detected floating in the cell culture medium even up to 70 h p.i. Evidence is presented that Pla1 has a role in merosome release.

Additional information
See mutant RMgm-5204 expressing a C-terminal 3xHA-mCherry-tagged version of Pla1 with expression in blood stages and liver stages

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1423100
Gene Model P. falciparum ortholog PF3D7_0814400
Gene productputative phospholipase, DDHD1
Gene product: Alternative namePA-PLA1, Pla1
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationFor deleting PbPla1, two homology regions were amplified from the 5’ and 3’ untranslated regions (UTRs) of the gene using primer pairs 1147/1148 (F1) and 1149/1150 (F2) and cloned at XhoI/SalI (F1) and NotI/AscI (F2), respectively, in the pBC-GFP-hDHFR:yFCU vector. The final construct was linearized by XhoI/AscI digestion
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6